Olanzapine or Risperidone for Acute Psychosis with Aggression
For adults with acute psychosis and aggression, I recommend starting with oral risperidone 2 mg/day or olanzapine 7.5-10 mg/day as first-line treatment, with intramuscular ziprasidone 20 mg or haloperidol 5 mg plus lorazepam 2 mg for immediate control of severe agitation. 1, 2, 1
Context-Dependent Treatment Algorithm
For Acute Agitation Requiring Immediate Control (Emergency Setting)
Intramuscular options are superior when rapid tranquilization is needed:
- First choice: IM ziprasidone 20 mg demonstrates rapid efficacy with notably fewer movement disorders (extrapyramidal symptoms, dystonia) compared to haloperidol 2
- Alternative: IM haloperidol 5 mg PLUS lorazepam 2 mg - this combination produces more rapid sedation than monotherapy and reduces the high dystonia risk of haloperidol alone 2
- Avoid haloperidol monotherapy when other options exist, as acute dystonia rates are unacceptably high (up to 19-fold increased risk) 3
The 2006 emergency medicine guidelines provide Level B evidence that benzodiazepines (lorazepam or midazolam) or conventional antipsychotics (haloperidol) are effective monotherapy, but combination therapy is safer and more effective 2.
For Ongoing Treatment After Stabilization (Inpatient/Outpatient)
Atypical antipsychotics are strongly preferred over typical antipsychotics:
The 2005 early psychosis guidelines explicitly state that extrapyramidal side-effects must be avoided to encourage future adherence, and although typical antipsychotics may reduce positive symptoms, they are less well tolerated even at low doses 1.
Specific dosing recommendations:
- Risperidone: Start 2 mg/day (can increase to maximum 4 mg/day in first-episode psychosis) 1
- Olanzapine: Start 7.5-10 mg/day (can increase to maximum 20 mg/day) 1
Critical Considerations for Aggression Specifically
When aggression poses significant risk to others, the guidelines indicate inpatient care may be required 1. The evidence shows:
- Ziprasidone IM significantly decreased restraint time compared to conventional therapy in psychiatric emergency settings 2
- Haloperidol plus promethazine showed superior tranquilization by 20 minutes with dramatically fewer adverse effects (11-fold reduction) compared to haloperidol alone 3
- Droperidol provided faster sedation than haloperidol but carries FDA black box warning for dysrhythmias, though large safety series suggest this risk may be overstated 2, 4
Important Caveats and Pitfalls
Avoid these common errors:
Do not use haloperidol monotherapy in coercive situations when alternatives exist - this could be considered unethical given the high dystonia risk 3
Lorazepam alone is as effective as haloperidol for acute agitation (multiple Class II studies), with fewer side effects 2. Consider benzodiazepine monotherapy for undifferentiated agitation before assuming antipsychotic is needed.
Anticholinergic caution: In patients with anticholinergic or sympathomimetic drug intoxication, antipsychotics can paradoxically worsen agitation due to their anticholinergic properties 2
Dose limitations matter: Maximum 4-6 mg haloperidol equivalent in first-episode psychosis to stay within limits of extrapyramidal side-effects 1
Clozapine for treatment resistance: The 2020 APA guidelines provide Level 1B evidence that clozapine should be used for treatment-resistant schizophrenia AND when risk for aggressive behavior remains substantial despite other treatments 5
Quality of Evidence Assessment
The emergency management recommendations come from 2006 guidelines with Class II evidence showing ziprasidone and combination haloperidol-lorazepam as effective options 2. The 2025 umbrella review confirms haloperidol, olanzapine, and lorazepam remain most frequently studied, with combination therapy (haloperidol plus promethazine) effectively reducing aggression with lower adverse effects 6.
For ongoing treatment, the 2005 early psychosis guidelines provide the clearest dosing recommendations favoring atypical antipsychotics 1, supported by the 2020 APA guidelines recommending antipsychotic treatment with monitoring (Level 1A evidence) 5.
The evidence consistently shows atypical antipsychotics have superior tolerability profiles, which directly impacts long-term adherence and quality of life - the outcomes that matter most beyond immediate symptom control.